Ulcerative Colitis

• Genetic susceptibility with defective barrier function: Genome-wide association studies (GWAS) have identified over 200 genetic loci associated with UC, including mutations in IL23R, JAK2, and genes encoding tight junction proteins (claudins, occludin). These genetic variants impair the intestinal epithelial barrier by reducing tight junction integrity and antimicrobial peptide production. The compromised epithelial barrier permits increased bacterial antigen translocation across the mucosa, triggering downstream immune activation. Importantly, UC patients demonstrate increased intestinal permeability even in unaffected relatives, suggesting barrier defects precede inflammation.

• Dysregulated innate immune activation and pattern recognition: The epithelial barrier breach allows increased interaction between luminal microbiota and pattern recognition receptors (PRRs), particularly toll-like receptors (TLRs) and nucleotide-binding oligomerization domain-containing protein 2 (NOD2). Aberrant TLR signaling in UC leads to excessive production of pro-inflammatory cytokines including TNF-α, IL-6, and IL-8 by intestinal macrophages and dendritic cells. Unlike Crohn's disease, UC demonstrates a predominantly Th2-mediated response with increased IL-5 and IL-13, though Th1 and Th17 responses also contribute. Innate lymphoid cells (ILCs) and γδ T cells produce increased IL-13, driving tissue damage and mucus depletion.

• Impaired mucosal immune tolerance and loss of regulatory T cells (Tregs): UC is associated with reduced frequency and function of FOXP3+ regulatory T cells and decreased production of the anti-inflammatory cytokine IL-10. Dysregulated epithelial-derived signals fail to promote appropriate Treg differentiation and homing. This permits expansion of pathogenic Th2 and Th17 cells that secrete pro-inflammatory mediators perpetuating chronic inflammation. The shift from tolerance to inflammation involves dysregulation of aryl hydrocarbon receptor (AhR) signaling, which normally promotes barrier function and Treg development through interactions with dietary metabolites.

• Microbiota dysbiosis as trigger and consequence: UC patients demonstrate profound changes in gut microbiota composition (dysbiosis) characterized by reduced bacterial diversity, decreased Firmicutes (particularly Faecalibacterium prausnitzii, a short-chain fatty acid [SCFA] producer), and altered Bacteroidetes. These alterations reduce production of the anti-inflammatory SCFA butyrate, which normally maintains barrier function, promotes Treg differentiation, and provides colonocyte energy. Dysbiosis permits expansion of pathogenic bacteria and increased lipopolysaccharide (LPS) exposure, further amplifying TLR4-mediated inflammation. Dysbiosis both precedes and is perpetuated by active inflammation, creating a vicious cycle.

• Epithelial barrier disruption and mucus layer depletion: Active UC involves loss of mucus-producing goblet cells and reduced mucin (MUC2) expression, compromising the protective mucus layer. Increased intestinal permeability is mediated by pro-inflammatory cytokines (particularly IL-13 from Th2 cells) that disrupt tight junction claudins and occludin expression. Enhanced apoptosis of epithelial cells, driven by TNF-α and Fas-FasL interactions, contributes to mucosal erosions and ulceration. The damaged epithelium becomes highly permeable to luminal antigens and bacteria, establishing a self-perpetuating cycle of antigen exposure and immune activation.

• Effector immune mechanisms causing tissue damage: Activated mucosal T cells and B cells produce tissue-damaging mediators including TNF-α, lymphotoxin, and IL-6. Neutrophil recruitment via IL-8 and other chemokines results in neutrophil-mediated epithelial damage through release of reactive oxygen species (ROS), proteases, and antimicrobial peptides. Antibody responses including IgG and IgA against bacterial antigens and self-antigens cross-react with colonic epithelial determinants. The net result is chronic mucosal inflammation characterized by increased intraepithelial lymphocytes, infiltration of lamina propria immune cells, crypt distortion, and ulceration.

• Environmental and dietary modifiers: Cigarette smoking paradoxically protects against UC development and reduces disease activity, possibly through nicotine-mediated immunosuppression and increased mucus production. High-fat, low-fiber diets may worsen dysbiosis and reduce SCFA production. Nonsteroidal anti-inflammatory drugs (NSAIDs) increase UC flare risk by disrupting tight junctions and enhancing epithelial permeability. Appendectomy in childhood reduces UC risk, possibly by altering immune education. These environmental factors modulate genetic predisposition and dysbiosis to determine disease phenotype and severity.

• Genetic predisposition (primary determinant): First-degree relatives of UC patients have 5–10 times increased lifetime risk. Twin studies demonstrate 15–20% concordance in monozygotic twins versus 0–5% in dizygotic twins, indicating substantial but incomplete genetic contribution. Over 200 susceptibility loci identified through GWAS, many involved in immune regulation (IL23R, JAK2, STAT3), barrier function (CDH1, claudins), and bacterial sensing (NOD2). These genes are neither necessary nor sufficient individually, reflecting complex polygenic inheritance. Single nucleotide polymorphisms (SNPs) in these loci modify disease predisposition and may influence treatment response, making genetic testing increasingly clinically relevant.

• Dysbiosis and altered microbiota composition: Dysbiosis characterized by reduced microbial diversity, decreased Firmicutes (especially F. prausnitzii and Roseburia species), and increased pathobionts precedes and perpetuates UC. Early-life antibiotic exposure, which disrupts microbiota maturation, increases UC risk. High-fat, low-fiber diets that reduce SCFA-producing bacteria increase disease susceptibility. Conversely, high-fiber diets and diets rich in polyphenols enhance butyrate-producing bacteria and reduce flare risk. The dysbiosis is both a cause and consequence of inflammation, making microbiota restoration therapeutically important.

• Environmental triggers and modifiable factors: Nonsteroidal anti-inflammatory drugs (NSAIDs) increase flare risk by 1.5–3 fold through epithelial barrier disruption and inhibition of protective prostaglandins. Cigarette smoking is the single most protective environmental factor (dose-dependent risk reduction), a paradoxical finding supporting nicotine-mediated mechanisms. Oral contraceptives slightly increase UC risk through estrogen-mediated immune activation. Appendectomy in childhood reduces UC risk by approximately 70%, possibly by altering mucosal immune education through loss of lymphoid tissue. Stress and psychological factors worsen disease through neuroimmune mechanisms (increased gut permeability, dysbiosis, Th17 expansion).

• Infections as potential triggers: Some viral and bacterial infections may trigger UC in genetically susceptible individuals, though no single causative pathogen has been definitively established. Measles infection in childhood increases UC risk. Clostridium difficile superinfection complicates UC and may trigger exacerbations. Prior infection with enteroviruses and reovirus exposure correlates with increased anti-viral antibodies in UC patients, though causal relationships remain uncertain. Dysbiotic microbiota may permit pathogenic bacterial expansion, including adherent-invasive E. coli (AIEC), which associates with UC and Crohn's disease but is not universally present.

• Demographic and socioeconomic factors: Developed nations with high sanitation and antibiotic use show higher UC incidence than developing countries, supporting the "hygiene hypothesis" implicating reduced early microbial exposure. Higher socioeconomic status paradoxically associates with increased UC risk, possibly reflecting dietary patterns and antibiotic use. Jewish ethnicity (particularly Ashkenazi) confers 2–3 fold increased risk independent of geography. Male and female incidence is roughly equal, though some data suggest slight female predominance in older populations. Caucasian populations show higher incidence than Asian and African populations, though incidence in these groups is rising with Westernization.

Cardinal Gastrointestinal Symptoms

• Diarrhea with blood and mucus: The hallmark symptom, occurring in >90% of patients, reflects both increased colonic motility from inflammatory mediators (prostaglandins, leukotrienes) and mucosal ulceration causing bleeding. Patients report urgency to defecate and 4–20+ stools daily during flares (compared to <4 daily in remission). Bloody diarrhea is present in 80% of patients with active disease and may be the sole presenting symptom in mild disease. The bleeding reflects mucosal ulceration and increased submucosal vascularity; gross blood in stool without systemic symptoms initially may be mistaken for hemorrhoids, delaying diagnosis.

• Abdominal pain and cramping: Present in 70–90% of patients during active disease, typically localized to the left lower abdomen and worse before defecation. Pathophysiology involves inflammatory cytokine-mediated visceral hypersensitivity, increased motility, and mucosal ulceration activating nociceptors. Pain severity correlates with disease activity but does not always distinguish UC from other conditions. In severe UC, severe diffuse abdominal pain with rebound tenderness suggests toxic megacolon or perforation, representing medical emergencies.

• Urgency and tenesmus: Inflammatory mediators, mucosal ulceration, and increased luminal pressure activate rectal sensory nerves, creating urgency and sensation of incomplete evacuation. Patients experience frequent, sometimes uncontrollable urges to defecate, particularly at night (nocturnal diarrhea in 50% of patients). This symptom significantly impacts quality of life and sleep, warranting early aggressive treatment even in mild-moderate disease.

• Mucus passage: Increased mucus reflects goblet cell hyperplasia and increased mucin secretion in response to inflammation, though paradoxically there is concurrent goblet cell loss and mucus layer depletion in active disease. Patients may notice prominent mucus in stool or without stool between defecations.

Systemic Manifestations (in moderate-severe disease)

• Fever: Present in 20–30% of patients with moderate-severe disease, indicating significant systemic inflammatory response. Fever reflects elevated pro-inflammatory cytokines (IL-6, TNF-α) and potential concurrent infections. High fever (>39°C) with severe symptoms raises concern for toxic megacolon, perforation, or secondary infection.

• Weight loss and malnutrition: Occurring in 30–40% of patients with moderate-severe disease, weight loss reflects inadequate caloric intake due to diarrhea and abdominal pain, increased intestinal losses of protein and blood, and systemic inflammation increasing metabolic demands. Anemia from chronic bleeding and inflammation (hepcidin-mediated iron sequestration) contributes to fatigue. Micronutrient deficiencies (B12, folate, iron, zinc, calcium) occur from malabsorption and increased losses, particularly in extensive disease.

• Fatigue and malaise: Present in most patients with active moderate-severe disease, predominantly from anemia, systemic inflammation (elevated IL-6, TNF-α), and sleep disruption from nocturnal diarrhea. Fatigue often disproportionately impacts quality of life compared to gastrointestinal symptoms.

Physical Examination Findings (in active disease)

• Abdominal tenderness: Left lower quadrant or diffuse abdominal tenderness on palpation reflects mucosal inflammation and peritoneal irritation. Severe tenderness with rebound and guarding suggests severe inflammation with risk of perforation. Abdominal distention may indicate toxic megacolon or severe colonic dilation.

• Perianal findings absence: Unlike Crohn's disease, UC characteristically does NOT cause perianal disease (abscesses, fistulas, skin tags). Presence of perianal disease should prompt reconsideration of diagnosis toward Crohn's disease or other conditions.

• Aphthous ulcers and oral ulceration: Oral aphthous ulcers occur in 5–10% of UC patients and may precede or accompany bowel disease exacerbations. These represent extraintestinal manifestations and help confirm IBD diagnosis when present with colitis.

Important Clinical Variants

• Mild-moderate disease (most common presentation): <4 stools daily with blood, minimal systemic symptoms, normal hemoglobin and albumin. Patients may delay seeking care, attributing symptoms to dietary indiscretion or hemorrhoids. Diagnosis often requires explicit inquiry about stool frequency and blood.

• Severe/fulminant colitis: >6 bloody stools daily, severe abdominal pain, fever, systemic toxicity, anemia (hemoglobin <10.5 g/dL), hypoalbuminemia (<3.0 g/dL). This represents a medical emergency with risk of toxic megacolon, perforation, and sepsis. Requires hospitalization, intensive management, and consideration for early surgical intervention if inadequate response to medical therapy.

• Proctitis (distal disease): Inflammation limited to rectum and sigmoid; presents with urgency, tenesmus, and passage of mucus and blood without watery diarrhea. May initially present only with constipation paradoxically due to rectal irritation. Often mild but symptomatic, disproportionately impacts quality of life.

• Fulminant colitis with toxic megacolon: Acute-onset severe diarrhea (>10 stools daily), high fever (>39°C), severe abdominal pain, dehydration, colonic dilation (>6 cm) on imaging, and risk of perforation. Mortality 1–5% even with aggressive treatment. Requires ICU-level care and urgent gastroenterology and surgery consultation.

• Silent/asymptomatic colitis: 5–10% of UC patients with ongoing histologic and endoscopic inflammation but minimal or no symptoms. These patients are at ongoing risk for cancer and require continued surveillance and treatment.

Clinical History and Assessment

• Symptom characterization: Obtain detailed history of bowel symptoms including stool frequency, presence of blood and mucus, urgency, nocturnal symptoms, and temporal pattern (continuous vs intermittent). Duration of symptoms >4 weeks supports chronic IBD over infectious enterocolitis. Ask about previous episodes, triggers, impact on work/quality of life, and extraintestinal symptoms (joint pain, eye symptoms, skin lesions). Family history of IBD increases pretest probability. Review medications, particularly NSAIDs, which can trigger or worsen UC. Assess smoking status (protective factor).

Laboratory Tests (Essential)

• Complete blood count (CBC): Hemoglobin <10.5 g/dL indicates significant chronic blood loss and inflammatory anemia; acute severe disease may show hemoglobin >13 g/dL from hemoconcentration due to dehydration before hemorrhage. Elevated white blood cell count (>11,000/μL) reflects acute inflammatory response and systemic toxicity; marked elevation (>15,000/μL) raises concern for toxic megacolon or secondary infection. Elevated platelets (>400,000/μL) indicate chronic inflammation. Albumin <3.0 g/dL indicates significant protein losses and nutritional compromise, associated with worse prognosis.

• Inflammatory markers: Elevated C-reactive protein (CRP, normal <8 mg/L) and erythrocyte sedimentation rate (ESR, normal <20 mm/hr) correlate with disease activity and guide treatment intensity. CRP more rapidly reflects

Acute severe UC (hospitalized, treat as an emergency)

• Stabilize first: IV fluids, transfuse for symptomatic anemia, correct potassium/magnesium, and exclude C. difficile and CMV superinfection before escalating immunosuppression.
• Prophylactic anticoagulation: ACG recommends pharmacologic VTE prophylaxis (e.g., low-molecular-weight heparin) in hospitalized IBD patients despite hematochezia — inflammation creates a prothrombotic state that outweighs bleeding risk.
• IV corticosteroids (methylprednisolone or hydrocortisone) are first-line. Reassess around day 3; inadequate response mandates rescue therapy with infliximab (anti-TNF) or IV cyclosporine, with early colorectal surgery consultation.

Outpatient induction

• 5-Aminosalicylates: topical mesalamine suppository for proctitis, enema for left-sided disease; oral mesalamine (or sulfasalazine) for extensive disease. Combined oral plus topical 5-ASA beats either alone. These act locally on colonic epithelium (PPAR-γ agonism, NF-κB inhibition).
• Corticosteroids: budesonide MMX or prednisone for 5-ASA failure — induction only, never maintenance, because of adrenal suppression, bone loss, and hyperglycemia.

Escalation for moderate-to-severe or steroid-dependent disease

• Anti-TNF agents: infliximab, adalimumab, golimumab; screen for latent TB and hepatitis B first.
• Anti-integrin: vedolizumab blocks α4β7–MAdCAM-1 gut homing — gut-selective, favorable infection profile.
• IL-12/23 or IL-23 blockade: ustekinumab.
• Small molecules: JAK inhibitors (tofacitinib, upadacitinib) and the S1P modulator ozanimod; FDA boxed warnings for thrombosis, MACE, and malignancy make JAK inhibitors post-anti-TNF options.
• Thiopurines (azathioprine) are steroid-sparing maintenance, not induction; check TPMT/NUDT15 first.

Emergencies

• Toxic megacolon: transmural inflammation paralyzes colonic smooth muscle (nitric oxide–mediated), producing dilation with systemic toxicity. Signals: fever, tachycardia, distention, and transverse colon >6 cm on plain abdominal radiograph. Paradoxical decrease in stool frequency with worsening pain is ominous. Colonoscopy and barium enema are contraindicated.
• Perforation and peritonitis: thinned, dilated colon ruptures; free air on upright film or CT. Highest mortality complication; requires emergent colectomy.
• Massive lower GI hemorrhage: diffuse ulceration of a friable, hypervascular mucosa; a minority of urgent colectomies are performed for bleeding.
• Venous thromboembolism: inflammation raises fibrinogen and factor VIII and lowers antithrombin — DVT/PE risk is elevated even during bleeding flares.

Disease-related, non-emergent

• Colorectal cancer: chronic inflammation drives a dysplasia–carcinoma sequence that is often flat and multifocal (unlike sporadic adenomas). Risk rises with disease duration, extensive colitis, and coexisting PSC; ACG recommends surveillance colonoscopy with dye-spray/high-definition biopsies beginning about 8 years after diagnosis, and beginning at PSC diagnosis with annual intervals.
• Primary sclerosing cholangitis: signaled by cholestatic liver enzymes (elevated alkaline phosphatase); beading on MRCP. Carries cholangiocarcinoma risk and runs independent of colitis activity.
• Strictures: uncommon in UC — assume malignancy until proven otherwise.
• Infectious superinfection: C. difficile and CMV colitis mimic or precipitate flares; test before escalating immunosuppression.

Treatment-related

• 5-ASA: acute interstitial nephritis (rising creatinine — monitor), rare pancreatitis; sulfasalazine adds sulfa hypersensitivity, hemolysis in G6PD deficiency, folate deficiency, and reversible oligospermia.
• Thiopurines: myelosuppression (TPMT/NUDT15 variants), hepatotoxicity, pancreatitis, non-melanoma skin cancer, lymphoma — including hepatosplenic T-cell lymphoma in young men on thiopurine plus anti-TNF.
• Anti-TNF: reactivation of latent TB and hepatitis B, demyelination, drug-induced lupus.
• Cyclosporine: nephrotoxicity, hypertension, seizures (worse with hypomagnesemia/hypocholesterolemia).
• Post-IPAA pouchitis: presents with increased stool frequency and urgency; responds to antibiotics such as ciprofloxacin or metronidazole.

• Continuous, rectum-upward inflammation limited to mucosa and submucosa is the defining contrast with Crohn's skip lesions and transmural disease. Crypt abscesses with neutrophils, goblet cell depletion, and crypt architectural distortion are the histologic buzzwords; granulomas argue for Crohn's.
• Radiographic buzzwords: lead-pipe colon (loss of haustra from chronic scarring) and pseudopolyps (islands of regenerating mucosa between ulcers). Backwash ileitis is the distractor — mild terminal ileal inflammation can occur in pancolitis and does not make it Crohn's.
• Single best next step in suspected toxic megacolon: plain abdominal radiograph, not colonoscopy. Endoscopy and barium enema risk perforation. Also stop loperamide, opioids, and anticholinergics.
• The association examiners love: UC plus a cholestatic liver panel equals primary sclerosing cholangitis — confirm with MRCP showing beading; p-ANCA is often positive and PSC mandates colonoscopic surveillance starting at PSC diagnosis per ACG.
• Smoking is protective in UC and harmful in Crohn's — a favorite reversal. Appendectomy in youth also lowers UC risk.
• Extraintestinal manifestations that parallel bowel activity: peripheral arthritis, erythema nodosum, episcleritis. Those that do not: ankylosing spondylitis/sacroiliitis (HLA-B27), pyoderma gangrenosum, uveitis, and PSC.
• Total proctocolectomy is curative in UC but never in Crohn's — a classic stem discriminator. Ileal pouch–anal anastomosis preserves continence; watch for pouchitis treated with ciprofloxacin or metronidazole.
• **Before escalating immunosuppression in a "flare," test stool for *C. difficile***, and consider CMV in steroid-refractory disease. Treating a superinfection as a flare is the trap.
• Do not use steroids for maintenance — maintenance is 5-ASA for mild-to-moderate disease and a biologic, thiopurine, or small molecule for moderate-to-severe disease per AGA.